VARITECT Solution for Injection 5g/1250IU/50 ml %v/v Ireland - English - HPRA (Health Products Regulatory Authority)

varitect solution for injection 5g/1250iu/50 ml %v/v

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection - 5g/1250iu/50 ml %v/v

VARITECT 5g/1250IU/50 ml %v/v Solution for Injection Ireland - English - HPRA (Health Products Regulatory Authority)

varitect 5g/1250iu/50 ml %v/v solution for injection

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection - 5g/1250iu/50 ml %v/v

VARITECT %v/v Solution for Injection Ireland - English - HPRA (Health Products Regulatory Authority)

varitect %v/v solution for injection

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin varicella-zoster - solution for injection - %v/v

MEGALOTECT Solution for Infusion 50 Units/ml Ireland - English - HPRA (Health Products Regulatory Authority)

megalotect solution for infusion 50 units/ml

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin cytomegalovirus - solution for infusion - 50 units/ml

MEGALOTECT Solution for Infusion 50 Units/ml Ireland - English - HPRA (Health Products Regulatory Authority)

megalotect solution for infusion 50 units/ml

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin cytomegalovirus - solution for infusion - 50 units/ml

MEGALOTECT 50 Units/ml Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

megalotect 50 units/ml solution for infusion

biotest pharma gmbh - human plasma protein >95% immunoglobulins immunoglobulin cytomegalovirus - solution for infusion - 50 units/ml

ALBIOMIN 20 % Israel - English - Ministry of Health

albiomin 20 %

kamada ltd, israel - plasma protein fraction - solution for infusion - plasma protein fraction 200 mg/ml - protein c - protein c - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendation.